Top Tech Companies in Boston, MA (4,162)

Profitability: Record adjusted operating income and margin accompanied the growth, with management lifting 2026 adjusted operating income guidance to a higher margin level. Operating leverage was emphasized alongside strong second‑quarter results.

Resilient & Sustainable Growth: Gross profit accelerated year over year into Q2 2026 (after an even stronger Q1), and full‑year 2026 gross profit guidance was raised meaningfully. Leadership framed gross profit as the clearer indicator of underlying momentum given revenue mix effects.

Cost & Operational Efficiency: Efficiency measures, including running a leaner organization, boosted margins and contributed to record profitability. Leaders also pointed to continued strength into the second half with healthy monetization and risk metrics, indicating efficient scaling.

Investor Backing & Capital Strength: Recent financings include a strategic Series C with Dassault Syst�fsmes/Medidata (March 2025) and a Series D in April 2026 led by Boehringer Ingelheim tied to CT-155 commercialization. The restructuring with Boehringer also involved additional funding as commercialization responsibilities shifted to Click.

Product Line Growth: FDA authorizations for Rejoyn (MDD, 2024) and CT-132 (migraine prevention, 2025), plus the acquisition of AspyreRx (type 2 diabetes), expand the marketed and near-market portfolio. The launch of "Click SE" and CT-155s Breakthrough designation and positive pivotal data further broaden the offering toward potential submission.

Strategic Partnerships: Collaborations with Boehringer Ingelheim, Otsuka, and Dassault Syst�fsmes/Medidata, along with a 2026 venture with Ultrahuman, indicate strong external validation and routes to commercialization. Partner activity includes Boehringer transferring commercialization duties for CT-155 to Click.

Strong Revenue Growth: Net revenue rose 14% year over year in Q2 2026 (12% currency‑neutral) to $9.3B, with first‑half 2026 up 15% and full‑year 2025 up 16% (15% currency‑neutral). These results indicate sustained top‑line momentum across recent periods.

Diversified Revenue Streams: Value‑Added Services & Solutions grew 20% in Q2 2026 (18% currency‑neutral) and 23% in 2025, outpacing Payment Network growth. This mix shift adds a faster‑growing second engine alongside the core network.

Resilient & Sustainable Growth: Transaction fundamentals remained healthy in Q2 2026—gross dollar volume +8% to $2.9T, cross‑border +12%, and switched transactions +9% (local‑currency). Multi‑year growth from 2025 into the first half of 2026 underscores durable momentum.

Strong Revenue Growth: Revenue rose about 23% year over year in Q2 2026 and 24% for full-year 2025, with ARR up 25% and GPV up 22% reinforcing a scaling top line. Guidance for 2026 recurring gross profit growth of roughly 23–25% further underpins momentum.

Profitability: Operating income and EPS roughly doubled year over year in Q2 2026 (operating income $152M vs. $80M; diluted EPS $0.26 vs. $0.13). Management also highlighted rising adjusted EBITDA and improved net income alongside recurring gross profit expansion.

Market Expansion: New offerings (e.g., Toast Drive‑Thru) and enterprise wins/expansions (e.g., Best Western, TGI Fridays UK, multi‑unit brands like Caribou Coffee and Potbelly) support broader adoption. The footprint reached about 180,000 total locations as of June 30, 2026, up roughly 22% year over year.

Profitability: Margins and earnings are expanding, with Q1 FY2026 adjusted EBITDA up, gross margin at 30.1%, and positive net income. FY2025 also delivered record free cash flow alongside margin expansion.

Customer Loyalty & Retention: Autoship represents a large, recurring base at 84.4% of Q1 FY2026 net sales, growing at a double‑digit pace. Rising net sales per active customer and cross‑category engagement point to stickier spend and retention.

Diversified Revenue Streams: Pet health services are scaling through SmartPak and the Modern Animal acquisition, complementing core e‑commerce with clinics and pharmacy. The Modern Animal deal is expected to add over $125M in annualized run‑rate revenue and expand clinics from 18 to 47, with additional openings planned in FY2026.

Profitability: Earnings and underwriting margins improved materially, with a full‑year 2025 combined ratio of 88.4% and year‑to‑date 87.3% in the first half of 2026 alongside higher net income. First‑half 2026 net income reached $4.686B versus $2.870B a year earlier, reflecting stronger underwriting and lower catastrophe losses.

Investor Backing & Capital Strength: Total equity increased to $44.1B by June 30, 2026, and core operating companies were upgraded to A+ by S&P on July 21, 2026. These markers indicate a fortified balance sheet and capacity to support selective expansion.

Resilient & Sustainable Growth: Deliberate portfolio pruning and disciplined underwriting (e.g., sale of Western European operations and other exits) reduced reported premiums while aiming to raise returns and lower volatility. The approach is characterized as “growing better” rather than “growing bigger,” prioritizing margin quality over volume.

Investor Backing & Capital Strength: Recent securitizations and facility upsizes—culminating in a July 2026 $525 million raise that lifted committed capacity to nearly $700 million—signal strong access to capital and liquidity for expansion. The July ABS was reported as oversubscribed, reinforcing capital‑markets support.

Strong Revenue Growth: Appearance on the 2026 Inc. 5000 list, which ranks companies by multi‑year revenue growth, points to a rising top line. This recognition sits alongside stepped‑up origination capacity and cumulative funding that has surpassed $5 billion since inception.

Product Line Growth: The company now offers both revenue‑based financing and loans with ticket sizes from roughly $5,000 to $500,000, expanding beyond its original focus. This broader product set can widen addressable demand and support scaling.

Profitability: The company achieved full-year profitability at the group level in 2025, building on earlier platform-level profitability. This indicates improving operating leverage alongside growth.

Strong Revenue Growth: Annual recurring revenue rose to $218M in 2025 from $177M in 2024, showing renewed momentum versus the prior year. This expansion is supported by additional large-enterprise customer wins and bookings growth.

Diversified Revenue Streams: Newer offerings are contributing incremental monetization, with Mirakl Connect generating ARR and Mirakl Ads seeing rising ad spend and client additions. The expanding seller network and the launch of Nexus further broaden potential revenue sources.

Strong Revenue Growth: Revenue is rising briskly, with the latest quarter up year over year and full‑year FY2026 guidance raised for both revenue and ARR. Prior billings and deferred revenue growth indicate healthy demand heading into FY2026.

Strong Market Position & Advantage: Independent analyst evaluations place the company as a leader in SSE/SASE and note frequent inclusion on enterprise shortlists. A broad global footprint and regulatory certifications bolster competitiveness in regulated and international markets.

Product Line Growth: Expansion in newer offerings—such as Data Security, AI‑focused modules, and Zero Trust Branch—shows meaningful traction. Metered, non‑seat‑based solutions accounted for a sizable share of new ACV, suggesting broader monetization beyond core seats.

Strong Market Position & Advantage: The FAA selected ASI in June 2026 to help modernize the National Airspace System through a multi-year program that brings its Flyways AI into core ATC operations. This selection signals scale-up potential and long-term revenue visibility.

Customer Loyalty & Retention: Alaska Airlines adopted Flyways in 2021 and renewed the partnership in 2024, citing operational and fuel-efficiency benefits. Alaska’s subsequent reports and white papers describe ongoing, production use, indicating continued value delivery.

Market Expansion: Partnerships announced in 2026 with Joby Aviation for eVTOL integration and with National Grid to apply “operational AI” to the electric grid show movement into adjacent markets beyond traditional airlines. These moves broaden relevance across aviation and critical infrastructure.

Investor Backing & Capital Strength: Funding milestones include a $71M Series C in February 2022 and total disclosed capital of about $114.5M, with backers such as Accel, Insight Partners, and Tiger Global. This capital base supports multi‑year scaling while the company continues executing without a newly announced post‑2022 round.

Innovation-Driven Growth: Product expansion since 2024 centers on AI-focused capabilities such as measuring the impact of AI coding tools, the AI Impact Dashboard (2024), and a smarter Jellyfish Assistant (March 2026). Partnerships (e.g., Augment Code) and ongoing research outputs (e.g., the 2026 State of Engineering Management) indicate an active roadmap aligned to emerging demand.

Strong Market Position & Advantage: Recognition includes placement as a Leader in Gartner’s inaugural 2026 Magic Quadrant for Developer Productivity Insight Platforms and sustained Leader status on G2’s Software Development Analytics Tools grid through 2026. Case studies with well-known brands and broader availability via AWS Marketplace (since 2023) reinforce category presence.

Strong Market Position & Advantage: Repeated Leader placements in Gartner’s DEX Magic Quadrant (2024–2026) and Forrester’s 2024 EUEM Wave indicate durable competitive standing and sustained category momentum. These recognitions coincide with communications citing 1,200–1,500+ customers and 20M+ endpoints, underscoring broad enterprise adoption.

Product Line Growth: New offerings such as Adopt on Infinity (2025) and the Spark personal IT agent (2026), plus integrations like GoTo/Rescue and a government-focused AWS Marketplace listing, expand use cases and routes to market. The 2024 acquisition of AppLearn further broadened capabilities into digital adoption.

Investor Backing & Capital Strength: A late‑2025 majority investment by Vista Equity Partners at an approximately $3B valuation signals strong external confidence and provides resources for scaling. This step-up from the 2021 round supports continued product and go‑to‑market execution.

Resilient & Sustainable Growth: Square gross profit and payment volumes are rising with signs of acceleration in 2026; Q2 2026 gross profit reached about $1.16B and GPV increased at a low‑teens rate year over year. Management also raised the full‑year outlook at the Block level, indicating momentum in which Square is contributing.

Market Expansion: Traction with larger, multi‑location sellers and strong international GPV growth indicate expansion beyond very small businesses. U.S. GPV also accelerated to its strongest pace since Q2 2023, complementing faster non‑U.S. growth.

Innovation-Driven Growth: Hardware and AI are highlighted as fast‑compounding capabilities, and Square Financial Services has begun processing acquiring volume. An expanded ISO and partner ecosystem is bringing in more new sellers and deepening product adoption.

Strong Revenue Growth: Revenue expanded rapidly, with FY2025 up 83% to about $1.27B and Q1/Q2 2026 up 36% and 22% year over year, respectively. Management also raised 2026 revenue guidance to approximately $1.595–$1.605B.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with Diagnostics up 34.7% in Q1 and 20% in Q2 2026 and Insights/data licensing up 36% in Q2 alongside about $200M in new licenses. Rising oncology test volumes (28–31% YoY) and accelerating MRD tests (~4,700 in Q4 2025 to ~9,000 in Q2 2026) reinforce multiple growth engines.

Profitability: The company achieved its first GAAP-profitable quarter in Q2 2026 (net income about $5.6M; Adjusted EBITDA ~$8.0M). Guidance points to further improvement in 2026, indicating progress toward sustained profitability.

Strong Revenue Growth: Revenue is reported to have grown 26% in FY2024, alongside roughly 30% ARR growth in 2023 after surpassing the $100M milestone in 2022. This indicates sustained top-line expansion across consecutive years.

Profitability: The company reports remaining profitable and cash‑flow positive while growing in FY2024. This suggests operational discipline alongside expansion.

Investor Backing & Capital Strength: A July 2024 majority investment led by Vista Equity Partners valued the company at about $1.2B, with participation from TCV and KKR. This financing signals external confidence and provides resources for further expansion.

Investor Backing & Capital Strength: Formation Bio closed a $372M Series D on June 26, 2024 led by a16z with significant participation from Sanofi, bringing total funding to over $600M and at a material step-up in valuation. The capital is directed toward expanding its drug pipeline and AI platform.

Strategic Partnerships: A first‑in‑class AI collaboration with Sanofi and OpenAI (announced May 2024) has already produced Muse, an AI tool for patient recruitment. Additional partnering activity includes Sanofi’s 2025 deal for gusacitinib via a Formation subsidiary, signaling expanding commercial and technology ties.

Product Line Growth: Multiple in‑licensing moves in 2025–2026 (e.g., a CNS‑penetrant TYK2 inhibitor, a miR‑124 activator, and an anti‑CD226 program) broaden the portfolio. The first participant was dosed in a Phase 1 trial (BLKR201) on June 9, 2026, marking concrete clinical progression.

Strategic Partnerships: New relationships with firms such as Fidelity, Capital Group, Vanguard, and client wins like Elevation Point broaden distribution and embed the platform within major advisor ecosystems. These selections signal expanding access to workflows across large wealth programs.

Innovation-Driven Growth: Launches such as Vestmark Pulse and the opening of a Center for AI Research and Development indicate continued investment in AI-enabled capabilities. Growth in VAST and expanded tax-aware UMA features reinforce a steady cadence of new solutions.

Strong Market Position & Advantage: Scale of more than $2 trillion in assets on platform, millions of accounts, and support for 72,000+ advisors points to broad institutional adoption. Serving six of the ten largest managed-account platforms and VAS crossing $50B in AUM add evidence of an entrenched position at the high end of the market.

Innovation-Driven Growth: New AI-focused capabilities (e.g., AI Connectors built on Model Context Protocol) and a stated push to be an “AI platform for biotech R&D” signal ongoing product investment. Reported usage of Benchling AI across 500 biotech companies underscores adoption of these innovations.

Strategic Partnerships: The January 2026 collaboration with Lilly’s TuneLab is positioned to bring proprietary models to scientists across Benchling’s customer base. Acqui-hires of ReSync Bio and Sphinx Bio in 2025 were used to accelerate the AI roadmap.

Strong Revenue Growth: ARR was independently estimated around the low-$200 millions by mid-2024 with year-over-year increases, indicating continued top-line expansion. While the pace has moderated versus earlier years, the trajectory remains positive.

Investor Backing & Capital Strength: Large late-stage financing and valuation momentum signal strong access to capital, including a $250M Series E and corroborated unicorn-scale valuations. Capital depth is further reinforced by indications of continued fundraising interest.

Strategic Partnerships: Embedded distribution with Zillow Rentals’ AI Assist, powered by EliseAI, is reported to drive higher renter engagement and application behavior. Such channel access expands reach and evidences measurable impact in real-world funnels.

Strong Revenue Growth: Company disclosures indicate surpassing $200M in ARR with continued acceleration from earlier milestones. Adoption signals across large operators align with sustained top-line expansion.

Strong Revenue Growth: Recent quarters and the FY2025 comparison show sustained double‑digit top‑line increases alongside robust gains in payment volume. Guidance was raised for FY2026, reinforcing expectations for continued expansion.

Profitability: Adjusted EBITDA and margins expanded while the company achieved GAAP profitability in FY2025 and posted a profitable first quarter in 2026. Management also points to further margin expansion for FY2026.

Market Expansion: Hundreds of new client wins and marquee enterprise deals were highlighted across regions, with momentum spanning education software, travel/hospitality, and B2B. The enlarging client footprint aligns with upgraded growth targets.